Question 75

Taking both prasugrel and aspirin for post-myocardial infarction care increases the risk of severe bleeding.

Using prasugrel and aspirin together without appropriate therapeutic monitoring significantly elevates the risk of severe bleeding, which is a critical concern in post-myocardial infarction management.

A) Toxic epidermal necrolysis

Toxic epidermal necrolysis is a severe skin reaction, typically associated with certain medications, but it is not a recognized risk associated with the concurrent use of prasugrel and aspirin. Therefore, this option is incorrect in the context of post-myocardial infarction care.

B) Photosensitivity

Photosensitivity refers to an increased sensitivity to sunlight, which is generally linked to specific medications or conditions. However, prasugrel and aspirin do not significantly cause photosensitivity, making this option incorrect for the question regarding therapeutic monitoring and bleeding risks.

C) Severe bleeding

The combination of prasugrel and aspirin is known to enhance antiplatelet effects, thereby increasing the likelihood of severe bleeding complications. Without proper monitoring, patients may be at a heightened risk for such adverse effects, justifying this option as the correct answer.

D) Dehydration

Dehydration is not a direct consequence of taking prasugrel and aspirin together. It is typically associated with fluid loss or inadequate fluid intake, rather than the pharmacological interactions of these medications. Thus, this option does not pertain to the risks involved with their combined use.

Conclusion

Severe bleeding is a well-documented risk when combining prasugrel and aspirin, especially without proper therapeutic monitoring. The other options do not accurately reflect the serious complications that can arise from this medication combination, thereby reinforcing that severe bleeding is the primary concern in this context.